Topics Comments

 < Previous page    Next page > 
Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
Sino Biopharmaceutical Limited 2022-09-16T12:05 財經茄呢啡 美國總統拜登簽署行政命令,將促使更多生物醫藥企業留在美國本土生產,以消減對外國依賴。生物醫藥股受壓,藥明生物勁挫19.94%,收報53.4元,見3個月低位,並為表現最差藍籌股。石藥集團瀉2.51%,收報7.78元。中國生物制藥 跌0.75%,收報3.98元。
Sino Biopharmaceutical Limited 2022-08-24T20:12 財經茄呢啡 中國生物製藥(1177)表示,隨著市場環境不斷變化,科興的新冠疫苗銷量下降,實質盈利貢獻僅4.69億元人民幣。
Sino Biopharmaceutical Limited 2022-08-24T20:12 財經茄呢啡 中國生物製藥主營業務收入均錄得增幅,新產品收入升24.6%至66.1億元;抗腫瘤用藥收入升16.7%至49.6億元;創新藥收入升14.2%至34.9億元。集團正進行臨床試驗和申報生產之在研產品共418件,其中抗腫瘤用藥230件、呼吸系統用藥31件、肝病用藥29件、心腦血管用藥16件。
Sino Biopharmaceutical Limited 2022-07-15T12:28 財經茄呢啡 盈利能力方面,疫苗和海運業成最大贏家。機構投資者較為看中的淨資金回報率指標,位列第一的是科興生物,去年該公司盈利546億元ROE高達92%,智飛生物和中國生物制藥也進入前十。由於國際運價上升,東方海外(國際)和中遠海控分別以74.6%和67.1%位列ROE榜第二、第三位。
Sino Biopharmaceutical Limited 2022-07-08T12:20 財經茄呢啡 今天早盤,生物醫藥板塊大漲。權重股中國生物制藥漲超5%,生物科技ETF港股盤中一度漲2.8%。截止10:52,該ETF交投持續活躍,成交額接近5000萬。
Sino Biopharmaceutical Limited 2022-07-08T12:20 財經茄呢啡 南向資產再次賣入中國生物制藥955.54萬股,錄得連續6日賣入。現在,港股通共持有中國生物制藥73900.73萬股。日前,公司收購F-STAR 抗體藥物管線版圖再拓展。西部證券直言,考慮公司銷售基本盤穩定,研發管線豐富,保持「買進」評級。
Sino Biopharmaceutical Limited 2022-07-08T12:20 財經茄呢啡 格隆匯7月6日亅億帆醫藥發布,截止報告披露日,交易各方均已完成有關交易的全部交割事宜。億帆香港、中國生物制藥分別向億一生物支付了全部新股認購款,合計7000萬美元;億一生物完成了億帆香港、中國生物制藥的股權登記並出具了股東登記證書。
Sino Biopharmaceutical Limited 2022-07-01T12:25 財經茄呢啡 南向資產再次賣入中國生物制藥955.54萬股,錄得連續6日賣入。現在,港股通共持有中國生物制藥73900.73萬股。日前,公司收購F-STAR 抗體藥物管線版圖再拓展。西部證券認為,考慮公司銷售基本盤穩定,研發管線豐富,保持「買進」評級。
Sino Biopharmaceutical Limited 2022-06-24T12:11 財經茄呢啡 截至2022年6月23日收盤,中國生物制藥報收於4.5元,上揚2.74%,換手率0.25%,成交量4654.09萬股,成交額2.08億元。投行對該股的評級以買進為主,近90天內共有7家投行給出買進評級,近90天的目標均價為7.1。西部證券最新一份研報給予中國生物制藥買進評級,目標價4.76。
Sino Biopharmaceutical Limited 2022-06-24T12:11 財經茄呢啡 波司登21年年度純利約20.62億元同比增20.6%;快狗打車將於今天正式於港交所上市;互太紡織21年年度營收超60億元;佐丹奴國際獲周大福代理人溢價18.2%提現金要約;中國生物制藥擬以每股7.12美元要約收購F-STAR;信義儲電增長光伏膠膜生產線;白雲山中止分拆廣州醫藥到境外上市。
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.